CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medivir AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medivir AB
Lunastigen 5, 2 tr
Phone: +46 854683100p:+46 854683100 HUDDINGE, 141 22  Sweden Ticker: MVIRMVIR
Business Summary
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board UliHacksell 74 5/5/2021 5/3/2018
Chief Executive Officer JensLindberg 53 1/24/2022 1/24/2022
Chief Financial Officer MagnusChristensen 50 1/24/2022 8/12/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Medivir Personal AB Box 1086 Huddinge Sweden

Business Names
Business Name
Medivir
Medivir AB
Medivir Personal AB
8 additional Business Names available in full report.

General Information
Number of Employees: 10 (As of 9/30/2024)
Outstanding Shares: 112,156,392 (As of 9/30/2024)
Shareholders: 8,450
Stock Exchange: STO
Fax Number: +46 84076439


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024